Klinikum Darmstadt GmbH — Clinical Trial Site

38 Registered trials

15 Currently recruiting

Organisation

Klinikum Darmstadt GmbH

Location

Darmstadt, Germany

Identifier

ORG-100033067

Address

Grafenstrasse 9, 64283, Germany

Departments

#40288: Dermatology
3106: Dermatology
9170: Dermatology
Department of Dermatology
Department of Oncology and Hematology (Med. Klinik V)
Dermatology
Dermatology Department
Frauenklinik
Hautklinik
Hematology
Institut für Radioonkologie und Strahlentherapie
Klinikum Darmstadt GmbH
Klinikum Darmstadt GmbH Medizinische Klinik V - Hämatologie, Onkologie und Palliativmedizin
Med. Klinik II
Medizinische Klinik II
Medizinische Klinik II-Gastroenterologie, Hepatopankreatologie, Diabetologie und Pneumonie
Medizinische Klinik V
Medizinische Klinik V - Hämatologie, Onkologie und Palliativmedizin
Medizinische Klinik V - Onkologie und Hämatologie
Medizinische Klinik V / Haematologie
Medizinische Klinik V Hämatologie / Onkologie
N/A
NA

Clinical trials at this site (38)

Search interface

Randomized Phase III Study of Standard Intensive Chemotherapy versus Intensive Chemotherapy with CPX-351 in Adult Patients with Newly Diagno… Ended

2023-503670-21-00 Patients with newly diagnosed AML and intermediate- or 5 2019-08-28
Treatment for previously untreated patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) with an IDH1 or IDH2 mutatio… Ended

2022-502832-37-00 Acute myeloid leukemia 5 2019-03-01
Evaluation of Upadacitinib in Combination with Topical Corticosteroids in Adolescent and Adult Patients with Moderate to Severe Atopic Derma… Ended

2022-502937-24-00 Atopic Dermatitis 5 2019-01-02
A randomized phase III trial assessing the benefit of the addition of isatuximab to lenalidomide / bortezomib / dexamethasone (RVd) inductio… Ended

2024-513464-26-00 Multiple Myeloma 5 2018-10-18
A Study of the Efficacy and Safety of Brensocatib in Adults with Moderate to Severe Hidradenitis Suppurativa Ended

2024-515959-38-00 Hidradenitis Suppurativa 4 2025-03-06
Randomized, Double-Blind, Placebo and Active Comparator Controlled Phase 3 Study of Efficacy and Safety of ESK-001 for Moderate to Severe Pl… Ended

2023-507193-40-00 Moderate to Severe Plaque Psoriasis 5 2025-01-16
A study to evaluate the efficacy and safety of subcutaneous sonelokimab compared with placebo in adult participants with moderate to severe … Ended

2024-511363-28-00 hidradenitis suppurativa (HS) 5 2024-09-24
A study to test the efficacy and safety of SAR442970 in adults with hidradenitis suppurativa Ended

2022-502370-17-00 Hidradenitis suppurativa 4 2023-11-14
A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (S… Ended

2022-501752-29-00 Hidradenitis Suppurativa 5 2023-06-15
This is a study to evaluate dose-flexibility of Upadacitinib in Adult Subjects with Moderate to Severe Atopic Dermatitis Ended

2023-504869-23-00 Dermatitis atopic 11 2023-05-31
A randomized phase III non-inferiority trial assessing lenalidomide, bortezomib and dexame-thasone induction therapy with either intravenous… Ended

2024-516300-41-00 Multiple Myeloma 5 2023-03-07
An extension study to learn if Bimekizumab is safe and works as a long-term therapy in adults with moderate to severe hidradenitis suppurati… Ended

2024-511035-10-00 Hidradenitis Suppurativa 5 2021-06-23
Evaluation of Upadacitinib in Adolescent and Adult Patients with Moderate to Severe Atopic Dermatitis (Eczema) – Measure Up 2 Ended

2022-502936-38-00 Moderate and Severe Atopic Dermatitis 5 2019-01-09
HD21 Ended

2024-518022-33-00 Advanced Stage of Hodgkin Lymphoma 5 2016-07-15